证券代码：688393 证券简称：安必平 公告编号：2025-009 广州安必平医药科技股份有限公司 关于会计政策变更的公告 本次会计政策变更是因财政部新发布的企业会计准则解释及相关要求 而进行的变更，无需提交公司董事会、股东会审议。 一、本次会计政策变更概述 （一）执行《企业会计准则解释第 17 号》 2023 年 10 月 25 日，财政部发布了《关于印发〈企业会计准则解释第 17 号〉 的通知》（财会〔2023〕21 号），对"关于流动负债与非流动负债的划分"、"关于 供应商融资安排的披露"以及"关于售后租回交易的会计处理"的内容进行进一 步规范及明确。该解释自 2024 年 1 月 1 日起施行。公司自 2024 年 1 月 1 日起执 行。 （二）保证类质保费用重分类 2024 年 3 月，财政部发布了《企业会计准则应用指南汇编 2024》，规定保证 类质保费用应计入营业成本。公司自 2024 年 1 月 1 日起执行。 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 本次会计政策变更系广州 ...

广州安必平医药科技股份有限公司 简式权益变动报告书 信息披露义务人1：诸暨高特佳睿安投资合伙企业（有限合伙） 注册地址：浙江省诸暨市暨阳街道人民中路356号十三层 通信地址：上海市长宁区虹桥路1438号古北国际财富中心二期1803B 股份变动性质：股份减少 签署日期：2025 年 3 月3 1 日 1 上市公司：广州安必平医药科技股份有限公司 上市地点：上海证券交易所 股票简称：安必平 股票代码：688393 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称《证券 法》）、《上市公司收购管理办法》（以下简称《收购管理办法》）、《公开 发行证券的公司信息披露内容与格式准则第 15 号——权益变动报告书》（以 下简称《准则 15 号》） 及其他相关的法律、法规和规范性文件编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《证券法》《收购管理办法》《准则15 号》的规定，本报告书已全 面披露信息披露义务人在广州安必平医药科技股份有限公司中拥有权益的股份 变动情况。 四、截止本报告书签署日，除本报告书披露的持股信息外，信息披露义务 人没有通过任何其他方式增加或 ...

广州安必平医药科技股份有限公司 关于持股 5%以上股东减持至 5%权益变动 证券代码：688393 证券简称：安必平 公告编号：2025-007 的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次权益变动属于减持计划，不触及要约收购。 权益变动后，诸暨高特佳睿安投资合伙企业（有限合伙）（以下简称"诸 暨高特佳"）持有广州安必平医药科技股份有限公司（以下简称"公司"）股份数 量从 5,169,768 股减少至 4,678,385 股，持有股份占公司总股本比例从 5.53%减 少至 5.00%，不再是公司持股 5%以上的股东。 权益变动后，诸暨高特佳及其一致行动人重庆高特佳睿安股权投资基 金合伙企业（有限合伙）（以下简称"重庆高特佳"）、杭州高特佳睿海投资合伙 企业（有限合伙）（以下简称"杭州高特佳"）、杭州睿泓投资合伙企业（有限合 伙）（以下简称"杭州睿泓"）、董事王海蛟先生合计持股 8,493,426 股，持股比 例 9.0773%。 本次权益变动不会导致公司控股股东、实际控制人发生变化。 ...

安必平688393 时间: 2025年3月28日星期五 50.44分综合得分 较强 34.56 元 当日主力成本 35.10 元 5日主力成本 37.90 元 20日主力成本 27.69 趋势方向 主力成本分析 元 60日主力成本 周期内涨跌停 过去一年内该股 涨停 2次 跌停 0 次 技术面分析 32.00 中期支撑位 目前短线趋势不慎明朗，静待主力资金选择方向； 目前中期趋势不慎明朗，静待主力资金选择方向 K线形态 ★光脚阴线★ 下跌信号 36.07 短期压力位 33.83 短期支撑位 42.50 中期压力位 资金流数据 2025年03月28日的资金流向数据方面 | 主力资金净流出757.49万元 | | --- | | 占总成交额-8% | | 超大单净流出256.97万元 | | 大单净流出500.52万元 | | 散户资金净流出141.76万 | 关联行业/概念板块 医疗器械 -0.55%、体外诊断 -0.58%、医疗器械概念 -0.94%、互联医疗 -1.04%等 （以上内容为自选股写手差分机完成，仅作为用户看盘参考，不能作为操作依据。） 风险提示：以上内容仅作为作者或者嘉宾的观点，不代表和讯的任 ...

安必平 20250314 摘要 • 安必平聚焦数字化病理，提供智慧病理科解决方案、病理能力提升及药企 合作诊断服务，覆盖硬件（全自动数字切片扫描系统）、软件（病理交流 平台 APP）和 AI（宫颈细胞学 AI 产品，已获二类证书）。 • 宫颈细胞学 AI 产品完成多中心临床科研评价，6,015 例研究显示特异性达 75%，显微镜图像和癌症诊断灵敏度达 100%，已获二类医疗器械证书， 并计划拓展至免疫组化等领域。 • 中国病理行业面临病理医生短缺（缺口 12 万）、资源分布不均、培训周 期长、建设难度高等困境，肿瘤发病率上升驱动精准诊断需求，政策支持 力度加大。 • 安必平持续高比例研发投入，2024 年前三季度研发投入占比营收 10.83%，积极申报重点项目，预计 2025 年 Q3 获 HPA16+2 宫颈癌筛 查产品证书，2026 年 Q1 获宫颈细胞学 AI 产品三类证书。 • 安必平与瑞金医院、华为合作构建大模型，提供全套病理科数字化解决方 案，包括切片机、数字化扫描仪、DCS 系统、病理专病库软件等，集成临 床、病理、分子信息和数字切片。 • 安必平通过与港科大广州联合成立数据智能实验室，规避直接 ...

Investment Rating - The report assigns a "Buy" investment rating for the company, marking its first coverage in this regard [9]. Core Insights - The company is one of the most comprehensive and diverse enterprises in the domestic pathology diagnosis field, having obtained over 800 relevant registrations and certifications by June 2024, suitable for various tumor screenings and diagnoses [2]. - The company has developed a rich digital pathology product system, with its IBL500 digital pathology slide scanner upgraded to a throughput of 480 slides, meeting high-throughput data requirements for building large pathology models [3]. - The integration of AI into the company's offerings aims to provide an automated, standardized, digitalized, and intelligent overall solution for pathology departments, significantly reducing the workload of pathologists and improving accuracy [4]. - Revenue projections for the company indicate a gradual increase, with expected revenues of 471 million, 533 million, and 609 million yuan for 2024, 2025, and 2026 respectively, alongside net profits of 26 million, 34 million, and 51 million yuan for the same years [5][11]. Summary by Sections Company Overview - The company has been deeply engaged in the pathology industry for 20 years, developing various technical platforms and related equipment, including LBP, IHC, FISH, digital pathology, and PCR [2]. Digital Pathology Development - The digital pathology segment is expanding, with digital products contributing 5.4979 million yuan in revenue in the first half of 2024, reflecting a year-on-year increase of 146.12% [3]. AI Integration - The company is working on a comprehensive solution that combines reagents, equipment, digital scanning, and AI interpretation, particularly in cervical cancer screening, enhancing diagnostic efficiency [4]. Financial Projections - The company’s revenue structure is shifting from HPV reagent sales, which are affected by centralized procurement, towards digital pathology services, with projected revenues and profits showing a positive trend from 2024 to 2026 [5][11].

Investment Rating - The report assigns a "Buy" investment rating for the company, marking its first coverage in this regard [9]. Core Insights - The company is one of the most comprehensive and diverse enterprises in the domestic pathology diagnosis field, having obtained over 800 relevant registrations and certifications by June 2024, suitable for various tumor screenings and diagnoses [2]. - The company has developed a rich digital pathology product system, with its IBL500 digital pathology slide scanner upgraded to a throughput of 480 slides, meeting high-throughput data requirements for building large pathology models [3]. - The integration of AI into the company's offerings aims to provide an automated, standardized, digital, and intelligent overall solution for pathology departments, significantly reducing the workload of pathologists and improving accuracy [4]. - Revenue forecasts for the company indicate a gradual increase, with projected revenues of 471 million, 533 million, and 609 million yuan for 2024, 2025, and 2026 respectively, alongside net profits of 26 million, 34 million, and 51 million yuan for the same years [5][11]. Summary by Sections Company Overview - The company has been deeply involved in the pathology industry for 20 years, developing various technical platforms and related equipment, including LBP, IHC, FISH, digital pathology, and PCR [2]. Digital Pathology Development - The digital pathology segment is expanding, with digital products contributing 5.4979 million yuan in revenue in the first half of 2024, reflecting a year-on-year increase of 146.12% [3]. AI Integration - The company is working on a comprehensive solution that combines reagents, equipment, digital scanning, and AI interpretation, particularly in cervical cancer screening, enhancing diagnostic efficiency [4]. Financial Projections - The company’s revenue structure is shifting from HPV reagent sales, which are affected by centralized procurement, to digital pathology services, with expected revenues and profits showing a positive trend from 2024 to 2026 [5][11].

Summary of the Conference Call Company and Industry Overview - The company, 安必平, focuses on tumor screening and precision diagnosis, offering products across six major areas: cytology, PCR, immunohistochemistry, FISH, digital pathology, and AI solutions. The strategic emphasis is on digitalization, intelligence, standardization, and precision [2][4][36]. Core Points and Arguments - **Product Development**: The company has launched an automated digital slide scanning system and a real-time microscopy sharing system, along with the 爱病理 APP, creating an online community for pathology professionals [2][5]. - **AI Product Performance**: The cervical cytology AI product has achieved a specificity of 75% and a sensitivity of 100% for histology and cancer diagnosis, significantly improving slide reading speed from an average of 3 minutes to 1.57 minutes [2][7]. - **Market Expansion**: The company plans to expand into immunohistochemistry, FISH, and collaborations with pharmaceutical companies, aiming for automation and quality standardization in pathology [2][8]. - **Data Accumulation**: Since 2017, the company has focused on data accumulation through open-source data, self-collection, and partnerships with major hospitals, establishing a robust data system for AI development [4][17]. - **Challenges in the Pathology Industry**: The industry faces a shortage of pathologists (approximately 120,000 needed), uneven resource distribution, long training periods, and high construction difficulties [6][14]. - **Future Revenue Growth**: The company anticipates a revenue increase of 10% to 20% by 2025, driven by the introduction of new products and market expansion efforts [4][34]. Additional Important Insights - **AI Integration**: Future products will not be sold independently as AI but will enhance existing business lines, creating competitive barriers [12][35]. - **Collaboration with Tech Giants**: The company collaborates with Tencent and Huawei to develop AI pathology solutions, leveraging their strengths in algorithms and computational power [20]. - **Regulatory Landscape**: The company expects to obtain additional medical device certifications, which will further solidify its market position [8][35]. - **Long-term Strategy**: The focus remains on simultaneous development of automation and intelligence to ensure the effectiveness and reliability of solutions [21][36]. - **Market Positioning**: The company aims to capitalize on the domestic market's shift towards local alternatives, especially in the context of imported products [11][12]. This summary encapsulates the key points discussed during the conference call, highlighting the company's strategic direction, product innovations, market challenges, and future growth expectations.

Financial Performance - Total revenue for 2024 was CNY 470.79 million, a decrease of 5.33% compared to the previous year[3] - Net profit attributable to shareholders was CNY 22.04 million, down 44.99% year-on-year[5] - Net profit excluding non-recurring items was CNY 13.70 million, a decline of 61.20% compared to the previous year[5] - Basic earnings per share decreased by 44.19% to CNY 0.24[3] Assets and Equity - Total assets at the end of the reporting period were CNY 1.36 billion, a decrease of 2.54% from the beginning of the period[5] - Shareholders' equity attributable to the parent company was CNY 1.26 billion, down 0.56% from the beginning of the period[5] Reasons for Decline - The decline in revenue and profit was primarily due to the implementation of centralized procurement policies affecting HPV products, leading to a gross profit reduction of approximately CNY 22 million[6] - Increased salaries for sales, marketing, and co-construction personnel contributed to the profit decline[6] Future Outlook - The company is expanding its professional talent team to accelerate market conversion of previous R&D results[5] Financial Reporting - The financial data presented is preliminary and unaudited, with final figures to be disclosed in the audited annual report[8]

证券代码：688393 证券简称：安必平 公告编号：2025-005 广州安必平医药科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次权益变动属于减持，不触及要约收购 本次权益变动不会使公司控股股东、实际控制人发生变化 本次权益变动后，股东诸暨高特佳睿安投资合伙企业（有限合伙）（以下 简称"诸暨高特佳"）及其一致行动人重庆高特佳睿安股权投资基金合伙企业（有 限合伙）（以下简称"重庆高特佳"）、杭州高特佳睿海投资合伙企业（有限合伙） （以下简称"杭州高特佳"）、杭州睿泓投资合伙企业（有限合伙）（以下简称"杭 州睿泓"）、董事王海蛟先生合计持有广州安必平医药科技股份有限公司（以下简 称"公司"或"安必平"）9,356,770 股，合计持股比例占公司总股本的 10.00%。 公司于近日收到股东诸暨高特佳、重庆高特佳、杭州高特佳、杭州睿泓 及王海蛟先生发来的《简式权益变动报告书》，现将其有关权益变动情况公告如 下： 一、本次权益变动基本情况 （一）信息披露义务人 1.诸暨高特佳 关于股东权益变动 ...